Clinical Trial Update: Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries

View source ↗

Summary

Humacyte's Acellular Tissue Engineered Vessel (ATEV) has been approved for marketing for vascular injuries, with an update noting expanded access for individual…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Injury

Drugs mentioned

• Acellular Tissue Engineered Vessel (ATEV)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Vascular System Injuries | Status: APPROVED_FOR_MARKETING